Brief: Phexxi Prevents 99% Of Pregnancies Per Act Of Intercourse In Post HOC Analysis Of Phase 3 Ampower Clinical Trial Data
16/06/2022 14:13
June 16 (Reuters) - Evofem Biosciences Inc EVFM.O :
* PHEXXI® PREVENTED 99% OF PREGNANCIES PER ACT OF
INTERCOURSE IN A
POST HOC ANALYSIS OF PHASE 3 AMPOWER CLINICAL TRIAL DATA
Source text for Eikon: ID:nPn9sXzhPa
Further company coverage: EVFM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evofem Biosciences
See all newsBrief: Evofem Biosciences Adds Additional Manufacturing Capacity For Phexx To Support Global Growth Strategy
Brief: HUB Cyber Security Expands Into Women's Health With Zero-Cash Acquisition Of Evofem Notes
Evofem Biosciences Q1 sales edge up on higher pricing
Evofem Biosciences Q3 net sales rise
Brief: Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting